Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310088504> ?p ?o ?g. }
- W4310088504 abstract "In recent decades, chimeric antigen receptor (CAR)-engineered immune effector cells have demonstrated promising antileukemic activity. Nevertheless, their efficacy remains unsatisfactory on solid cancers, plausibly due to the influence of tumor microenvironments (TME). In a novel mouse cancer model with a humanized immune system, tumor-infiltrating immunosuppressive leukocytes and exhausted programmed death protein-1 (PD-1)high T cells were found, which better mimic patient TME, allowing the screening and assessment of immune therapeutics. Particularly, membrane-bound programmed death ligand 1 (PD-L1) level was elevated on a tumor cell surface, which serves as an attractive target for natural killer (NK) cell-mediated therapy. Hematopoietic stem cell-derived CAR-NK (CAR pNK) cells targeting the PD-L1 showed enhanced in vitro and in vivo anti-solid tumor function. The CAR pNK cells and nivolumab resulted in a synergistic anti-solid tumor response. Together, our study highlights a robust platform to develop and evaluate the antitumor efficacy and safety of previously unexplored therapeutic regimens." @default.
- W4310088504 created "2022-11-30" @default.
- W4310088504 creator A5009068560 @default.
- W4310088504 creator A5012460197 @default.
- W4310088504 creator A5013033278 @default.
- W4310088504 creator A5017353282 @default.
- W4310088504 creator A5017789638 @default.
- W4310088504 creator A5023590429 @default.
- W4310088504 creator A5027067638 @default.
- W4310088504 creator A5027407351 @default.
- W4310088504 creator A5035273217 @default.
- W4310088504 creator A5041032041 @default.
- W4310088504 creator A5053417249 @default.
- W4310088504 creator A5056618658 @default.
- W4310088504 creator A5057368797 @default.
- W4310088504 creator A5065631427 @default.
- W4310088504 creator A5065729959 @default.
- W4310088504 creator A5077541065 @default.
- W4310088504 date "2022-11-25" @default.
- W4310088504 modified "2023-10-16" @default.
- W4310088504 title "Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model" @default.
- W4310088504 cites W1970684135 @default.
- W4310088504 cites W1971143968 @default.
- W4310088504 cites W2012087438 @default.
- W4310088504 cites W2060829712 @default.
- W4310088504 cites W2073300038 @default.
- W4310088504 cites W2087209798 @default.
- W4310088504 cites W2092166052 @default.
- W4310088504 cites W2096322385 @default.
- W4310088504 cites W2153447482 @default.
- W4310088504 cites W2178588353 @default.
- W4310088504 cites W2298503769 @default.
- W4310088504 cites W2298626553 @default.
- W4310088504 cites W2337320437 @default.
- W4310088504 cites W2345952503 @default.
- W4310088504 cites W2402433991 @default.
- W4310088504 cites W2402673078 @default.
- W4310088504 cites W2555282968 @default.
- W4310088504 cites W2560367415 @default.
- W4310088504 cites W2619886251 @default.
- W4310088504 cites W2725187299 @default.
- W4310088504 cites W2791291658 @default.
- W4310088504 cites W2792588868 @default.
- W4310088504 cites W2794800012 @default.
- W4310088504 cites W2801309958 @default.
- W4310088504 cites W2810715813 @default.
- W4310088504 cites W2890393634 @default.
- W4310088504 cites W2890762462 @default.
- W4310088504 cites W2891534701 @default.
- W4310088504 cites W2901262057 @default.
- W4310088504 cites W2901305534 @default.
- W4310088504 cites W2945590213 @default.
- W4310088504 cites W2948485623 @default.
- W4310088504 cites W2965413325 @default.
- W4310088504 cites W2972713173 @default.
- W4310088504 cites W2977648831 @default.
- W4310088504 cites W2979597115 @default.
- W4310088504 cites W2981274839 @default.
- W4310088504 cites W2992765180 @default.
- W4310088504 cites W2996286256 @default.
- W4310088504 cites W3017961509 @default.
- W4310088504 cites W3023611224 @default.
- W4310088504 cites W3027131407 @default.
- W4310088504 cites W3030448313 @default.
- W4310088504 cites W3038967738 @default.
- W4310088504 cites W3041177707 @default.
- W4310088504 cites W3054169481 @default.
- W4310088504 cites W3093752130 @default.
- W4310088504 cites W3117297774 @default.
- W4310088504 cites W3119838003 @default.
- W4310088504 cites W3125826904 @default.
- W4310088504 cites W3135760102 @default.
- W4310088504 cites W3136187250 @default.
- W4310088504 cites W3136367206 @default.
- W4310088504 cites W3136555745 @default.
- W4310088504 cites W3139410613 @default.
- W4310088504 cites W3151427897 @default.
- W4310088504 cites W3158278756 @default.
- W4310088504 cites W3161485051 @default.
- W4310088504 cites W3194919829 @default.
- W4310088504 cites W3199851436 @default.
- W4310088504 cites W4211017340 @default.
- W4310088504 cites W76522298 @default.
- W4310088504 doi "https://doi.org/10.1126/sciadv.add1187" @default.
- W4310088504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36417514" @default.
- W4310088504 hasPublicationYear "2022" @default.
- W4310088504 type Work @default.
- W4310088504 citedByCount "6" @default.
- W4310088504 countsByYear W43100885042023 @default.
- W4310088504 crossrefType "journal-article" @default.
- W4310088504 hasAuthorship W4310088504A5009068560 @default.
- W4310088504 hasAuthorship W4310088504A5012460197 @default.
- W4310088504 hasAuthorship W4310088504A5013033278 @default.
- W4310088504 hasAuthorship W4310088504A5017353282 @default.
- W4310088504 hasAuthorship W4310088504A5017789638 @default.
- W4310088504 hasAuthorship W4310088504A5023590429 @default.
- W4310088504 hasAuthorship W4310088504A5027067638 @default.
- W4310088504 hasAuthorship W4310088504A5027407351 @default.
- W4310088504 hasAuthorship W4310088504A5035273217 @default.
- W4310088504 hasAuthorship W4310088504A5041032041 @default.